Intranasal Oxytocin Proposed for Interstitial Cystitis Pain in Double-Blind Crossover Trial

Interstitial cystitis (IC), a painful bladder disorder, is often exacerbated by stress, leading to significant patient discomfort. Current treatments often fall short in providing comprehensive relief, especially for stress-related pain. Anecdotal evidence suggests a reduction in IC symptoms during postpartum lactation, a period associated with decreased stress and elevated levels of hormones like oxytocin. Researchers are investigating oxytocin's potential as an analgesic and anxiolytic agent, making it a promising candidate for stress-exacerbated chronic pain syndromes like IC.

Investigators propose a double-blinded, placebo-controlled crossover trial to assess intranasal oxytocin against intranasal saline. The study will enroll patients diagnosed with interstitial cystitis who experience some degree of continuous, daily pain. Participants will receive either intranasal oxytocin or intranasal saline, with a crossover design to allow each patient to serve as their own control. The primary endpoint will focus on changes in bladder pain, aiming to evaluate oxytocin's analgesic and anxiolytic properties in this specific patient population.